Impact of Post-Progression Therapy (PPT) on Survival in AVF2107, a phase III trial of bevacizumab (AVASTIN™) in the first-line treatment of metastatic colorectal cancer

被引：0
|
作者：
Hedrick, Eric [1 ]
Hurwitz, H. [2 ]
Sarkar, S.
Griffing, S.
Grothey, A. [3 ]
机构：
[1] Genentech Inc, Hematol Oncol, Summit, NJ USA
[2] Duke Univ, Durham, NC USA
[3] Mayo Clin, Rochester, MN USA
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [31] First-line bevacizumab (Avastin) with 5-fluorouracil/leucovorin prolongs progression-free survival in metastatic colorectal cancer (mCRC) patients who are not optimal candidates for irinotecan therapy.
    Kabbinavar, F
    Schulz, J
    McCleod, M
    Patel, T
    Hamm, J
    Hecht, J
    Perrou, B
    Griffing, S
    Nelson, B
    Novotny, W
    BIOMEDICINE & PHARMACOTHERAPY, 2005, 59 : S348 - S348
  • [32] Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC
    Mansmann, Ulrich Robert
    Sartorius, Ute
    Laubender, Ruediger Paul
    Giessen, Clemens Albrecht
    Esser, Regina
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] The impact of early tumor shrinkage on survival in WJOG4407G trial, a randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab in first-line treatment for metastatic colorectal cancer.
    Nagase, Michitaka
    Yamazaki, Kentaro
    Tamagawa, Hiroshi
    Ueda, Shinya
    Tamura, Takao
    Murata, Kohei
    Tsuda, Takashi
    Baba, Eishi
    Tsuda, Masahiro
    Moriwaki, Toshikazu
    Esaki, Taito
    Tsuji, Yasushi
    Muro, Kei
    Taira, Koichi
    Denda, Tadamichi
    Ando, Masahiko
    Morita, Satoshi
    Boku, Narikazu
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [34] A phase III comparison of FOLFOXIRI to FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC)
    Masi, G.
    Brunetti, I
    Murr, R.
    Benedetti, G.
    Evangelista, W.
    Picone, V
    Chiara, S.
    Merlano, M.
    Vitello, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 22 - 23
  • [35] Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
    Nipp, Ryan D.
    Ryan, David P.
    ONCOLOGIST, 2015, 20 (03): : 236 - 238
  • [36] Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    ANTICANCER RESEARCH, 2011, 31 (05) : 1777 - 1782
  • [37] The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer
    不详
    CLINICAL COLORECTAL CANCER, 2007, 6 (09) : 621 - 624
  • [38] Survival impact of KRAS mutation in metastatic colorectal cancer (mCCR) under first-line treatment
    Mathias, Maria Cecilia
    Neto, Felippe Lazar
    Gouveia, Mariana Carvalho
    Stangler, Lucas
    Claro, Mateus Zapparoli
    de Mello, Evandro Sobroza
    Sabbaga, Jorge
    Braghiroli, Maria Ignez
    Venchiarutti Moniz, Camila M.
    Hoff, Paulo Marcelo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Phase II Study of Bevacizumab, Capecitabine, and Oxaliplatin Followed by Bevacizumab Plus Erlotinib as First-Line Therapy in Metastatic Colorectal Cancer
    Munoz, Alberto
    Pericay, Caries
    Garcia-Giron, Carlos
    Alonso, Vicente
    Duenas, Rosario
    Cirera, Luis
    Rivera, Fernando
    Falco, Esther
    Alvarez Bustos, Inaki
    Salud, Antonieta
    ONCOLOGY RESEARCH, 2013, 21 (04) : 181 - 191
  • [40] A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial
    Tabernero, Josep
    Yoshino, Takayuki
    Stintzing, Sebastian
    de Gramont, Aimery
    Gibbs, Peter
    Jonker, Derek J.
    Nygren, Peter
    Papadimitriou, Christos
    Prager, Gerald W.
    Tell, Roger
    Lenz, Heinz-Josef
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (01): : 28 - 37
12345